AstraZeneca, a pharmaceutical company, completed the acquisition of Gracell Biotechnologies, a global clinical-stage biopharmaceutical company, for $1.2bn. “We look forward to working with AstraZeneca to accelerate our shared goal of bringing transformative cell therapies to more patients living with debilitating diseases. By combining our expertise and resources, we can unlock new ways to harness the Gracell FasTCAR manufacturing platform, which we believe has the potential to optimise the therapeutic profile of engineered T cells, to pioneer the next generation of autologous cell therapies,” William Cao, Gracell Biotechnologies Founder, Chairman and CEO.